NovoCare Direct, Hims, Ro, insurance, or personal-import. Post-crackdown, that's the GLP-1 menu. Pick by friction, not by molecule.

You're 47. The compounded semaglutide that ran you $250/mo through 2024 ghosted in early 2025. Your pharmacy stopped returning calls, then sent the "we can no longer fulfill" email.

You searched "Wegovy cheap" again. Hims says $199. NovoCare says $349. Ro says "qualify first." Reddit says $80 if you don't mind a Mumbai postmark.

These aren't the same product with different prices. They're five different operational stacks selling you the same peptide through five different friction tunnels. The price difference is the friction.

If you're outside the US — UK, Australia, EU — your customs lane and your TGA / MHRA / EMA framework changes the math, and we'll get to that in Lane 4.

Let me walk you through the five lanes — all post-compounding-crackdown, all current as of April 2026.

The 5-lane snapshot (read this first if you're on mobile)

That's the menu. The rest of this article is which lane fits which life. Full reference matrix at the bottom.

How we got here: the compounding lane closed

Briefly, because it's the context for everything else.

From 2022 through 2024-2025, semaglutide and tirzepatide were on FDA shortage lists. Section 503A of the Federal Food, Drug, and Cosmetic Act allows compounding pharmacies to make custom versions of drugs that are in shortage. That's how a lot of US patients got semaglutide for $200-400/mo without going through Novo Nordisk.

FDA declared the tirzepatide shortage resolved October 2024, and semaglutide February 21, 2025 — with a 503A grace period through April 22, 2025 and 503B through May 22, 2025. After that, the legal pathway for mass-produced compounded semaglutide closed. Most US compounding pharmacies pivoted, and the cheap-semaglutide-for-cash market lost its biggest US-domestic option.

What remained: brand at brand prices, telehealth bundling, insurance if you could get it, the manufacturer's own self-pay program, and personal-import.

Lane 1: NovoCare Direct — the manufacturer's own cash program

This is the option most patients still don't know exists, because Novo doesn't advertise it the way they advertise Wegovy ads on YouTube.

Verified pricing from novocare.com, April 2026:

• Wegovy Pen 0.25mg / 0.5mg: $199/mo for the first 2 months (new-patient promo), then $349/mo
• Wegovy Pen 1mg / 1.7mg / 2.4mg: $349/mo
• Wegovy Pen HD 7.2mg: $399/mo (post-promo)
• Wegovy Pill 1.5mg / 4mg: $149/mo (4mg promo through Aug 31, 2026; then $199/mo)

Friction profile: you still need a US-licensed prescription. NovoCare doesn't write prescriptions — it dispenses to patients who already have one. So you need a primary-care visit ($150-300 cash if uninsured, copay if insured) or a telehealth pre-visit, then route the script to NovoCare's pharmacy partner.

What this lane is good for: you have a prescription already, you don't have insurance coverage for obesity drugs, and you want manufacturer-direct sourcing without telehealth markup layered on top. It's roughly 70-75% off list price ($1,200-1,800/mo retail) for the same Novo pen.

What it isn't: cheap. $349/mo standard is $4,188/year — and Wegovy is, per STEP-1 extension data, an indefinite-treatment drug. ~$21,000 over 5 years.

Lane 2: Telehealth bundles (Hims, Ro)

Hims and Ro both reframed weight-loss after the compounding crackdown. They moved from compounded semaglutide as the cheap headline to bundled brand at competitive cash-pay prices, with monthly memberships.

Hims Weight Loss, verified April 2026:

• Wegovy Pill: from $149/mo
• Wegovy Pen: from $199/mo
• Ozempic: from $199/mo
• Zepbound Vial: from $299/mo
• Mounjaro: $1,899/mo (basically retail — telehealth doesn't subsidize the tirzepatide brand at the same volumes)
• Membership: $39 first month, $149/mo thereafter

That last line matters. Hims's "$199 Wegovy Pen" is $199 medication + $149 membership = $348/mo all in after the first month. Their first-month $39 trial is the hook. The advertised price is the medication-only line item.

So when Hims advertises "$199 Wegovy Pen," the honest math is: $238 first month ($39 intro membership + $199 med), $348/mo every month after. The $199 number on the landing page is never the number you actually pay long-term.

Ro Body, verified April 2026:

• Wegovy Pill: $149/mo intro for lower doses
• Wegovy Pen: $199/mo intro for lower doses
• "Prepay & Save" unlocks lower per-month rates if you commit annually
• Membership: $149/mo, or as low as $74/mo on annual prepay
• Some SKUs (Wegovy Pill, Zepbound KwikPen) are cash-pay only; others accept insurance billing

Ro's "Prepay & Save" structure is the same lock-in mechanic as a gym annual membership. You get a lower per-month rate, you eat the cancellation friction.

What these lanes are good for: you want the prescription, the questionnaire, and the medication delivered in one workflow. You don't have a primary-care relationship, you don't want one, and you'll pay the membership for the convenience. The brand is real Wegovy / Ozempic / Zepbound from Novo or Lilly — telehealth doesn't compound or generic-substitute, they just route prescriptions to retail pharmacy fulfillment.

What they aren't: discount programs. The headline price is medication-only. Read the membership line.

Lane 3: Insurance (the lottery ticket)

If your employer plan covers obesity drugs, you might land at $25-50/mo copay for Wegovy or Zepbound after prior auth.

The catch is whether they cover it. Most US commercial plans exclude obesity drugs entirely unless you have:

• BMI ≥30, or BMI ≥27 with one weight-related comorbidity (HTN, T2D, dyslipidemia, OSA), AND
• Prior authorization showing failed dietary intervention, AND
• Sometimes a step-therapy requirement (try metformin or phentermine first).

Even when covered, prior auth typically takes 4-12 weeks, and many plans drop coverage at year 2-3 once you've hit your weight goal — which interacts badly with the regain data (the 67% regain story).

What this lane is good for: you have BMI/comorbidity gate access AND a plan that covers it AND patience for prior auth. Then you're paying $300-600/year. It's by far the cheapest legal option in the US.

What it isn't: predictable. Year 1 covered doesn't mean year 3 covered. Plan formularies churn annually.

Lane 4: Personal-import (the offshore lane)

This is where the post-crackdown vacuum partly got filled.

In March 2026, Sun Pharma launched Noveltreat in India — a generic semaglutide injection in the same dose strengths as Wegovy (0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg pens), under DCGI approval (the Indian regulator). Torrent Pharmaceuticals had already shipped Sembolic in oral form (3mg / 7mg / 14mg, mirroring Rybelsus dosing).

Cost through LiberaCure-routed personal-import: $80-150/mo for the injection, $80-120/mo for the oral. Same peptide, different finished-product manufacturer, different regulatory frame.

Friction profile: no prescription required for the order itself, but the legal lane is personal-import for personal use under FDA's Personal Importation Policy. Lead time 2-4 weeks with customs variance. Cold-chain (2-8°C) handling is the supplier's responsibility — pens ship insulated direct from a licensed Indian pharmacy. Payment is crypto-only (BTC, USDT, LTC, XMR, ETH via NOWPayments) — that's the operational choice that lets the markup tier sit where it does.

Country-specific note (this part matters and most articles skip it): The US framework is FDA's Personal Importation Policy — discretionary, generally tolerated for 90-day personal supply with documented personal use. Australia runs a stricter regime — the TGA Personal Importation Scheme allows up to 3 months' supply of prescription medicine for personal use, but the TGA has been actively cracking down on commercial-scale offshore GLP-1 imports through 2025-2026, and customs interceptions are climbing. UK under the MHRA allows personal importation for personal use, but commercial advertising of personal-import GLP-1 to UK residents is restricted. EU member states each have their own framework — Germany, France, Spain treat this very differently from each other. None of these lanes are "illegal" for the patient personally importing, but enforcement posture varies. Our import-legality summary breaks it down by jurisdiction.

What this lane is good for: you're already self-managing dose titration, you understand it's personal-import (not US-domestic dispensing), and the absolute price floor matters more than next-day delivery. ~5-10% of Wegovy retail.

What it isn't: a substitute for clinical monitoring if you've never used GLP-1. First-time users probably want a telehealth lane (or PCP) for the initial titration where dose and side-effect calibration matters most. After you know your maintenance dose, the lane choice becomes more about logistics.

Lane 5: Compounded (mostly closed, narrowly open)

For completeness, since you might still see ads.

After the May 22, 2025 503B grace period ended, mass-compounding semaglutide for general patients became illegal. What remains legal is personalized compounding under 503A — meaning a specific prescriber writes a script for a specific patient with a documented clinical need that off-the-shelf Wegovy/Ozempic doesn't meet (e.g., a documented allergy to a specific excipient, a non-standard dose).

Most US compounding pharmacies that survived this transition operate under that narrower rule. Pricing in that residual lane: $250-500/mo, with friction (specific prescriber relationship, documented medical justification, narrower supply).

What this lane is good for: edge cases. You have a documented allergy to phenol or another Wegovy excipient and a prescriber willing to write a personalized compound. Otherwise, this lane isn't really open the way it was in 2023.

The friction-vs-price decision matrix

The metaphor: it's the airline ticket problem

You can fly NYC → LA five different ways for the same 6-hour seat.

Same plane, same destination, different operational stack. First-class is "no friction with status." Coach is "lowest price, longest line." Last-minute is "pay 4x for the convenience window." Frequent-flyer redemption is "free if you've stockpiled the right currency."

The seat is the same. You're paying for the friction profile that fits your week.

GLP-1 is the same. Five lanes, same peptide. The lane choice is what fits your life — insurance status, geographic location, prescription access, time-to-delivery requirement, willingness to self-titrate.

What about Mounjaro / Zepbound (tirzepatide)?

Same logic, slightly different lane economics.

Lilly runs LillyDirect (their cash-pay program), with Zepbound vials at $349-499/mo for self-pay (similar to NovoCare Direct's structure). Telehealth bundles offer Zepbound Vial at $299 medication-only (Hims), but the brand pen / Mounjaro list runs ~$1,899/mo at telehealth — basically retail. The brand pen subsidy that softens Wegovy doesn't exist on the tirzepatide side yet.

If you're on the BMI 27-29.9 borderline (overweight but not technically obese) with one weight-related comorbidity — HTN, T2D, dyslipidemia, OSA — you qualify clinically for both Wegovy and Zepbound under FDA labeling, but you're the patient most likely to get insurance-denied on prior auth (insurers tend to gatekeep harder at the lower BMI end). That cohort tends to land in the cash-pay or personal-import lanes by default, not by preference.

Indian generic tirzepatide hasn't fully launched yet (the patent landscape is messier — different patent expiries in different countries). When it does, expect a similar 5-lane structure to settle out within a year.

What to do this month

If you have insurance with obesity coverage:

1. Push prior auth for Wegovy or Zepbound. 4-12 weeks of paperwork.
2. If denied, formulary exception with STEP-1 trial citation.
3. If still denied, you're in the cash-payer pool.

If you're cash-paying, prescription-already-in-hand:

1. NovoCare Direct first — $349/mo Wegovy is the cheapest brand-direct lane, and it's the most overlooked option.
2. Compare against personal-import at your dose tier ($80-150/mo) if cost matters more than 1-3 day delivery.

If you're cash-paying, no prescription yet:

1. Telehealth bundle if you want one workflow. Hims or Ro, factor in $74-149/mo membership separately from medication line.
2. PCP visit + NovoCare if you'd rather have a clinical relationship. $150-300 visit cost, then $349/mo.
3. Personal-import if you've used GLP-1 before and know your maintenance dose. Read our import-legality summary first — US, UK, AU each have different personal-import frameworks, and your jurisdiction matters.

Either way, two protocol items:

1. Plan for indefinite use, not 6 months. GLP-1 isn't a course of antibiotics. Budget the lane accordingly.
2. DEXA or bioimpedance scan at baseline. ~$50-150 cash. The drug works, but you'll want to know if the loss is fat or lean mass.

A note on bias.

We route semaglutide orders. Be aware of that.

LiberaCure routes both formats of generic semaglutide through licensed personal-import pharmacies — Noveltreat (by Sun Pharma) for injection (0.25-2.4mg pens, mirroring Wegovy/Ozempic dosing) and Sembolic (by Torrent Pharmaceuticals) for oral tablets (3/7/14mg, mirroring Rybelsus dosing). We do not route brand-name Novo Nordisk pens, brand-name Eli Lilly tirzepatide, or US-compounded semaglutide.

So we have a financial reason to want this article to lead you toward "give it a try."

Read this with that in mind. The lane comparison above is what I'd tell a friend choosing between five legitimate options, not what maximizes reorder rate. Lane 1 (NovoCare) and Lane 3 (insurance) are real, fair choices for a lot of people, and we don't compete with either on convenience.

Sources:

• NovoCare Direct self-pay pricing, novocare.com, accessed April 2026 ($349-499/mo Wegovy Pen, $149-199/mo Wegovy Pill).
• Hims Weight Loss pricing page, hims.com/weight-loss, accessed April 2026 (Wegovy Pill $149/mo, Wegovy Pen $199/mo, Ozempic $199/mo, Zepbound Vial $299/mo, Mounjaro $1,899/mo; membership $39 first month, $149/mo thereafter).
• Ro Body pricing, ro.co/weight-loss, accessed April 2026 (Wegovy Pen $199/mo intro, Wegovy Pill $149/mo intro; membership $74-149/mo).
• FDA Drug Shortages Database — tirzepatide resolved October 2024; semaglutide resolved February 21, 2025 (503A grace through April 22, 2025; 503B through May 22, 2025).
• Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). N Engl J Med 2021;384:989. PMID 33567185
• DCGI/CDSCO public register — Sun Pharma Noveltreat (generic semaglutide injection) launched March 2026; Torrent Pharma Sembolic (generic oral semaglutide) on shelves March 2026.

Related:

• GLP-1 comprehensive guide — pillar
• Wegovy $1,800 vs LiberaCure-routed Noveltreat $80-150 — anatomy of the gap — sibling, brand-vs-generic price decomposition
• Stopping Ozempic: 67% regain in one year — why "lane choice" matters across years, not months

— LiberaCure editorial. We route generic medication through licensed personal-import pharmacies. We don't dispense, prescribe, or warehouse. Read more about why.